Octreotide as first-line treatment for women with metastatic breast cancer

James N. Ingle, Carl G. Kardinal, Vera J. Suman, James E. Krook, Alan K. Hatfield

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


Octreotide is a synthetic somatostatin analogue which has shown inhibitory activity against human breast cancer cells in culture. Ten patients with metastatic breast cancer and no prior hormonal therapy exposure received octreotide at 150 μg subcutaneously thrice daily. No objective responses were observed and the median time to treatment failure was short at 57 days.

Original languageEnglish (US)
Pages (from-to)235-237
Number of pages3
JournalInvestigational New Drugs
Issue number2
StatePublished - 1996


  • Metastatic breast cancer
  • Octreotide

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Octreotide as first-line treatment for women with metastatic breast cancer'. Together they form a unique fingerprint.

Cite this